INCAGN-1876

At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments Botensilimab/balstilimab combination data update selected for late-breaking oral session at the ESMO-GI conference in June 2023 FDA granted Fast Track Designation to the botensilimab/balstilimab combination in colorectal cancer in April 2023 At a plenary session at SGO, botensilimab/balstilimab combination showed 33% overall response rate in platinum-resistant ovarian cancer patients Phase II ACTIVATE trials expected to fully enroll in second half of 2023 AGEN2373 monotherapy data to be presented at ASCO in June 2023 Balstilimab/zalifrelimab data in the treatment of sarcoma to be presented at ASCO oral session in June 2023 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023. "With over 350 patients dosed with botensilimab in our Phase 1 study, we have demonstrated 20-50% response rates in 9 solid tumor cancers. These results suggest that botensilimab could provide significant benefit to patients who have not responded to or failed other available treatments,” said Dr. Garo Armen, Chief Executive Officer of Agenus. “Agenus is committed to advancing our development programs to make botensilimab available to patients ASAP." Botensilimab Combination Unprecedented activity in 70 patients with non-MSI-H colorectal cancer and 24 patients with recurrent platinum resistant/refractory ovarian cancer: Agenus presented botensilimab/balstilimab combination data at a late-breaking oral session at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) in January 2023 and at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer in March 2023 The combination showed unprecedented responses and survival benefit in 70 patients with non-microsatellite instability-high (non-MSI-H) colorectal cancer, including: 12-month overall survival of 63% (compared to 25% reported for standard of care) 1,2 Overall response rate of 23% (compared to 1-2%1,2 reported for standard of care and 1-5%3,4 reported for other PD-(L)1 + CTLA-4 combinations) In April 2023, the FDA granted Fast Track Designation to the botensilimab/balstilimab combination for the treatment of non-MSI-H/deficient mismatch repair (dMMR) metastatic colorectal cancer patients without active liver involvement who are resistant or intolerant to fluoropyrimidine, oxaliplatin, or irinotecan, and have also received a VEGF inhibitor, an EGFR inhibitor, and/or a BRAF inhibitor Agenus is conducting a global, randomized Phase 2 trial in this patient population under its ACTIVATE trial program, and a global Phase 3 trial is expected to commence in 2023 In 24 ovarian cancer patients who were resistant or refractory to platinum chemotherapy, the botensilimab/balstilimab combination showed a 33% response rate (compared to ~10% reported for standard of care5 and 3-10% for other PD-(L)1 + CTLA-4 combinations6,7) Agenus continues to enroll PD-(L)1 relapsed/refractory NSCLC patients in its Phase 1b study and plans to launch a randomized phase 3 study if the previously reported ~50% response rates continue Upcoming Presentations Updated data on the botensilimab/balstilimab combination in non-MSI-H metastatic colorectal cancer patients selected for a late breaking oral presentation at the upcoming ESMO World Congress on Gastrointestinal Cancer (ESMO-GI), to be held June 18 – July 1, 2023 in Barcelona, Spain Data from a single-arm, open-label Phase 2 study of balstilimab and zalifrelimab (1st generation CTLA-4) plus doxorubicin in patients with advanced sarcomas selected for oral presentation at the ASCO 2023 Annual Meeting, to be held June 2-6 in Chicago, IL Complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 in patients with advanced solid tumors will also be presented in a poster discussion at ASCO Clinical Pipeline and Corporate Partnerships Additional presentation at ASCO involving Agenus's clinical pipeline involving collaborations include: Abstract #424868: Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA) Abstract # TPS6104: Phase 2 Trial of Retifanlimab (anti–PD-1) in Combination With INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as First-Line Treatment in Patients With PD-L1–Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Abstract #2599: A Phase 1/2 Study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) With Advanced Solid Tumors Abstract #2541: A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers Agenus shareholders received dividend of shares in MiNK Therapeutics (NASDAQ: INKT) On May 1st, 2023, Agenus distributed a dividend of approximately 5,000,000 shares it owned of its subsidiary MiNK Therapeutics’ common stock to shareholders who held Agenus shares as of April 17, 2023, with a ratio of 0.0146 shares of MiNK (NASDAQ: INKT) per share of Agenus. The announced dividend distribution preceded MiNK's presentation of its lead product, agenT-797, an allo-INKT cell therapy, showing clinical and biomarker responses in solid tumor cancers at AACR in April 2023. This distribution allows Agenus shareholders to benefit from future growth of MiNK through direct ownership. The shares that were distributed as part of this dividend were not part of a new stock offering. First Quarter 2023 Financial Results: We ended our first quarter 2023 with a cash, cash equivalent and short-term investment balance of $189.2 million, compared to $193.4 million at December 31, 2022. Since quarter end we have raised $13.6 million through sales under our at market issuance sales agreement. For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share. Financial Highlights (in thousands, except per share data) (unaudited) March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 189,233 $ 193,358 Three months ended March 31, 2023 2022 Revenues, research and development $ 2,612 $ 6,740 Revenues, non-cash royalty 19,106 17,634 Revenues, other 1,184 1,567 Total Revenue 22,902 25,941 Research and development expenses 57,118 42,442 General and administrative expenses 18,237 18,953 Cost of service revenue 2,294 543 Other (income) loss (721 ) 191 Non-cash interest expense 17,273 14,952 Non-cash contingent consideration fair value adjustment (406 ) (536 ) Net loss $ (70,893 ) $ (50,604 ) Net loss per share attributable to Agenus Inc. common stockholders $ (0.22 ) $ (0.19 ) Cash used in operations $ 58,526 $ 52,391 Non-cash operating expenses $ 24,935 $ 21,069 Conference Call Date: May 9, 2023, 8:30am ET Dial-in numbers: 646-307-1963 (US-NY) & 800-715-9871 (Ex-US) Event ID: 9144113 Webcast A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at and via . References 1 Mayer et al. NEJM 2015 2 Grothey et al. Lancet 2013 3 Chen et al. JAMA Oncol. 2020 4 Overman et al. ASCO 2016 5 Mutch DG, et al. J Clin Oncol. 2007;25(19): 2811-2818 6 7 Hinchcliff et al. Gynecologic Oncology 2021 About Botensilimab Botensilimab is a novel, multifunctional CTLA-4 investigational antibody that has been designed to extend clinical benefits to “cold” tumors that have not historically responded to standard of care or investigational therapies, as well as to expand clinical benefit in “hot” tumors, where immunotherapies are approved but benefit only a minority of patients. In addition to binding to the CTLA-4 receptor, its Fc-enhanced structure induces a memory immune response, downregulates regulatory T cells, activates existing T cells, as well as primes and expands new T cells, thereby promoting a more effective and durable immune response to cancer. In a Phase 1 clinical study of more than 350 patients, botensilimab has demonstrated clinical responses in nine different cold and treatment-refractory solid tumor cancers, either alone or in combination with Agenus’ PD-1 antibody, balstilimab (data presented at ASCO GI 2023, SGO 2023, SITC 2022, and CTOS 2022). Agenus is conducting global, randomized Phase 2 trials in non-MSI-H colorectal cancer, melanoma, and pancreatic cancer as part of its ACTIVATE trial programs. Additional information about these botensilimab trials can be found at under the identifiers NCT05608044, NCT05630183, and NCT05529316, respectively. A global Phase 3 trial in non-MSI-H colorectal cancer is expected to launch in 2023. About AGEN2373 AGEN2373 is a novel anti-CD137 agonist that has been designed to activate T and NK cells while mitigating liver toxicities common to the CD137 target class. CD137 (4-1BB) is an activating receptor expressed on T and NK cells. Upon binging to CD137, AGEN2373 is designed to stimulate the growth and activation of cytotoxic T and NK cells, triggering a lasting memory response to cancer. AGEN2373 binds to a unique epitope designed to achieve this response specifically within the tumor microenvironment. This selective binding is designed to avoid serious side effects associated with CD137 activation in the liver that have been reported by competitor molecules. AGEN2373 has demonstrated preliminary clinical activity and has been well tolerated by patients without signs of liver toxicity (Tolcher et al. ASCO 2021). About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit and Twitter handle @MiNK_iNKT. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability pro our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: . Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Incyte's pipeline cuts will allow the pharma to funnel resources to “programs that can have a high impact for patients and for Incyte," according to CEO Hervé Hoppenot. Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various cancers—to focus on eight remaining programs. The Jakafi maker’s remaining R&D programs “have high potential,” Incyte CEO Hervé Hoppenot said in a May 2 release. The pipeline trim will allow the pharma to funnel its resources to “programs that can have a high impact for patients and for Incyte."    The company has ended phase 3 work on a small molecule PI3K inhibitor—known as parsaclisib—in warm autoimmune hemolytic anemia, citing the “challenging regulatory landscape associated with the PI3K class.” While several PI3K inhibitors have managed to snag FDA approval, the drug class has been frequently tied to serious or even fatal side effects. Last year, the FDA lost confidence in the safety profile of PI3K inhibitors for blood cancers after data from six randomized clinical trials indicated that four marketed PI3K inhibitors may shorten blood cancer patients’ life expectancy because of their toxicity. Since then, the agency said it would put the meds under a more stringent regulatory scope.   Incyte’s parsaclisib had also been assessed in a phase 3 trial as a combo treatment alongside the pharma’s approved JAK inhibitor Jakafi for certain cancers. However, the pharma’s first effort at building a better Jakafi regimen ended in failure after an independent data monitoring committee found it was on course to miss the primary endpoint of reducing spleen volume in patients with bone marrow cancer myelofibrosis, and the study was discontinued.     Incyte has also ended development of its adenosine program, which includes four separate assets. First on the list is INCB106385, which was being assessed in two separate phase 1 trials among patients with advanced solid tumors. One of those trials also evaluated INCA00186, which is being discontinued, alongside anti-GITR antibody INCAGN1876 in various cancers and INCB81776 in advanced malignancies. All the adenosine programs were discontinued based on early efficacy data, according to Incyte’s release. While Incyte continues to expand the reach of pemazyre—the first FDA-approved drug designed to specifically treat bile duct cancer—in non-U.S. countries, the pharma has ended a phase 2 clinical trial dubbed FIGHT-210 that was testing out the drug in non-small cell lung cancer. So what remains? One of the eight programs the company is zooming in on is INCB123667, a CDK2 inhibitor being studied in a phase 1 trial for patients with advanced malignancies. Another of the surviving programs is INCA33890, a bispecific antibody that has shown anti-tumor effects in preclinical studies. Alongside other discovery programs, Incyte continues to work to expand labels for its approved drugs.   Despite the R&D overhaul, the drug developer still seems to be investing in new science for its pipeline. Last month, Incyte paid out $7 million cash to use Biotheryx’s platform to identify and initially develop molecular glue degraders for “multiple historically undruggable oncology targets.” The deal gives Biotheryx the chance to make another $6 million in R&D funding and up to $347 million in milestone payments.